Physician profile
Kamaldeep Panach
NPI 1043501174
$2,266.19
in general payments reported to CMS, 2019-2025
22 companies · $801 in 2025
The $801 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $591 · 2023: $364 · 2024: $510 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,675.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $542.50 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $473.12 | 2022-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.31 | 2022-2024 | Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $203.14 | 2022-2025 | Repatha, Prolia, Evenity |
| Novo Nordisk INC | $138.35 | 2023-2025 | Rybelsus, Ozempic |
| Nevro Corp. | $114.33 | 2023 | Senza |
| Lilly USA, LLC | $63.13 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Madrigal Pharmaceuticals | $55.56 | 2025 | Rezdiffra |
| Sumitomo Pharma America, INC. | $54.47 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $52.57 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $50.82 | 2024-2025 | |
| Pfizer INC. | $48.24 | 2024 | |
| Edwards Lifesciences Corporation | $44.96 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Insulet Corporation | $31.74 | 2023 | Omnipod |
| Eisai INC. | $29.25 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.00 | 2022 | |
| Dexcom, INC. | $23.64 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $22.46 | 2022 | |
| Sanofi Pasteur INC. | $18.28 | 2025 | |
| Sanofi-Aventis U.S. LLC | $17.61 | 2025 | |
| Astellas Pharma US INC | $15.90 | 2022 | |
| Merck Sharp & Dohme LLC | $14.81 | 2025 | Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamaldeep Panach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.